US biopharma company Ardelyx (Nasdaq: ARDX) has entered into a license agreement that provides Japan’s Kyowa Hakko Kirin (TYO: 4151) with exclusive rights to develop and commercialize Ardelyx's lead investigational product, tenapanor, for the treatment of cardiorenal diseases, including hyperphosphatemia, in Japan.
Tenapanor is an oral, minimally systemic NHE3 inhibitor discovered and developed by Ardelyx that is in Phase III development in the USA for the treatment of hyperphosphatemia in patients with end-stage renal disease (ESRD) who are on dialysis. The drug is also in Phase III trials targeting irritable bowel syndrome with constipation.
Financial terms
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze